<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666965</url>
  </required_header>
  <id_info>
    <org_study_id>243-07-003</org_study_id>
    <nct_id>NCT00666965</nct_id>
  </id_info>
  <brief_title>A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients</brief_title>
  <official_title>A Placebo-Controlled Study for SPM 962 in RLS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate efficacy and safety of SPM 962 in
      Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group
      comparative study following once-daily multiple transdermal doses of SPM 962 within a range
      of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period</measure>
    <time_frame>Baseline, end of maintenance period at 6 weeks</time_frame>
    <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score.
The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Severity</measure>
    <time_frame>Baseline, 2 weeks, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.</time_frame>
    <description>CGI is a clinician-reported scale for assessing severity of illness.
The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI) Improvement</measure>
    <time_frame>Baseline, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.</time_frame>
    <description>The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline, every two weeks</time_frame>
    <description>PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates &quot;no difficulty&quot; and 21 indicates &quot;severe difficulty&quot;. A decrease in the scores means improvement.
The data at 6 weeks after dosing is shown.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)</measure>
    <time_frame>Baseline, every two weeks</time_frame>
    <description>Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IRLS Each Parameter</measure>
    <time_frame>Baseline, every two weeks</time_frame>
    <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually 'very severe') to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Idiopathic Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>inactive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPM 962</intervention_name>
    <description>transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>rotigotine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 20 and more and less than 80 years of age and is able to think about
             her/his participation at the time of informed consent.

          2. Subject meets the diagnosis of idiopathic RLS based on the 4 cardinal clinical
             features according to the IRLSSG/NIH.

          3. The following subject will be included in the study

               -  Subject is not currently receiving treatment for RLS.

               -  Subject has previously received treatment of either L-dopa or dopamine agonists
                  and efficacy was observed in either of drugs.

          4. At baseline, subject has a score of ≧ 15 on the IRLS sum score and RLS symptoms occur
             twice and more a week (≧score 2 in IRLS Question 7)

          5. Subject has a score of ≧ 4 on the CGI Severity score at baseline

        Exclusion Criteria:

          1. Subject has secondary RLS in association with renal impairment such as uremia，iron
             deficiency anemia, and drug associated symptoms.

          2. Subject has, is suspected of having or has a history of sleep disorders such as sleep
             apnea syndrome, narcolepsy, sleep attacks/sudden onset of sleep.

          3. Subject has additional clinically relevant concomitant diseases or symptoms such as
             polyneuropathy (including diabetic neuropathy), akathisia，claudication
             varicoses，muscle fasciculation，painful legs moving toes and radiculopathy.

          4. Subject has other central nervous diseases like Parkinson's disease, dimentia,
             progressive supranuclear paresis, multisystem atrophy, Huntington's Chorea,
             amyotrophic lateral sclerosis, or Alzheimer's disease.

          5. At screening or baseline, subject has psychiatric condition like confusion,
             hallucination, delusion, excitation, deliria, abnormal behaviour.

          6. Subject has orthostatic hypotension or systolic BP marks ≦ 100 mm Hg and with a
             decrease of BP from supine to standing position of ≧ 30 mm Hg.

          7. Subject has a history of epilepsy, convulsion etc.

          8. Subject has serious cardiac dysfunction and/or arrhythmias (e.g., congestive heart
             failure Class III or IV by NYHA, myocardial infarction, angina pectoris, conduction
             system dysregulations, second or third degree AV block, complete left bundle branch
             block, sick-sinus-syndrome, ventricular fibrillation within twelve months prior to
             enrollment).

          9. Subject has arrhythmia and receiving Class Ia antiarrhythmic drugs(e.g., quinidine,
             procainamide), Class III antiarrhythmic drugs (e.g., amiodarone, sotalol)

         10. At screening and baseline, subject develops serious ECG abnormality. Subjects has
             QTc-interval &gt;450 msec twice at screening. Subject has a the average QTc-interval from
             two ECGs &gt;450 msec in males and &gt;470 msec in females at baseline.

         11. Subject has long QT syndrome congenital.

         12. Subject has a serum potassium level &lt; 3.5 mEq/L at screening.

         13. Subject has a total bilirubin ≧3.0 mg/dL or AST(GOT) and/or ALT(GPT) greater than 2.5
             times the upper limit of the reference range (or ≧100 IU/L) at screening.

         14. Subject has BUN ≧ 30 mg/dL or serum creatinine ≧2.0 mg/dl at screening.

         15. Subject has a history of allergic reaction to topical agents such as transdermal
             patch.

         16. Subject is pregnant or nursing or woman who plans pregnancy during the trial.

         17. Subject pursues shift work or is subject to other continuous non-disease-related life
             conditions which do not allow regular sleep at night.

         18. Subject has autoimmune disease, chronic active hepatitis or immune deficiency
             disorder.

         19. Subject has a malignant neoplastic disease requiring therapy within twelve months
             prior to screening.

        19. Subject received an investigational drug from other clinical trial within the last 12
        months prior to baseline.

        20. Subject is judged to be inappropriate for this trial by investigator on the other than
        above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsuhisa Saito</last_name>
    <role>Study Director</role>
    <affiliation>New Product Evaluation Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2008</study_first_posted>
  <results_first_submitted>February 3, 2014</results_first_submitted>
  <results_first_submitted_qc>March 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SPM 962</keyword>
  <keyword>rotigotine</keyword>
  <keyword>Idiopathic Restless Legs Syndrome</keyword>
  <keyword>RLS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotigotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo transdermal patch</description>
        </group>
        <group group_id="P2">
          <title>2.25 mg/Day</title>
          <description>SPM962 maintein dose: 2.25 mg/day</description>
        </group>
        <group group_id="P3">
          <title>4.5 mg/Day</title>
          <description>SPM962 maintein dose: 4.5mg/day</description>
        </group>
        <group group_id="P4">
          <title>6.75 mg/Day</title>
          <description>SPM962 maintein dose: 6.75 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3 subjects (1 for each placebo, 4.5 mg/day and 6.75 mg/day arm) were excluded by criteria</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo transdermal patch</description>
        </group>
        <group group_id="B2">
          <title>2.25 mg/Day</title>
          <description>SPM962 maintein dose: 2.25 mg/day</description>
        </group>
        <group group_id="B3">
          <title>4.5 mg/Day</title>
          <description>SPM962 maintein dose: 4.5mg/day</description>
        </group>
        <group group_id="B4">
          <title>6.75 mg/Day</title>
          <description>SPM962 maintein dose: 6.75 mg/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="57"/>
            <count group_id="B4" value="56"/>
            <count group_id="B5" value="227"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.6" spread="13.1"/>
                    <measurement group_id="B2" value="50.6" spread="13.0"/>
                    <measurement group_id="B3" value="48.3" spread="14.1"/>
                    <measurement group_id="B4" value="51.0" spread="12.4"/>
                    <measurement group_id="B5" value="49.6" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period</title>
        <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually ‘very severe’) to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score.
The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.</description>
        <time_frame>Baseline, end of maintenance period at 6 weeks</time_frame>
        <population>Full analysis set (FAS), last observation carried forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>2.25 mg/Day</title>
            <description>SPM962 maintein dose: 2.25 mg/day</description>
          </group>
          <group group_id="O3">
            <title>4.5 mg/Day</title>
            <description>SPM962 maintein dose: 4.5mg/day</description>
          </group>
          <group group_id="O4">
            <title>6.75 mg/Day</title>
            <description>SPM962 maintein dose: 6.75 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change of International Restless Legs Syndrome Study Group Rating Scale (IRLS) Score From the Baseline to the End of Titration/Maintenance Period</title>
          <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually ‘very severe’) to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score.
The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.</description>
          <population>Full analysis set (FAS), last observation carried forward (LOCF)</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="7.2"/>
                    <measurement group_id="O2" value="-10.7" spread="6.3"/>
                    <measurement group_id="O3" value="-14.4" spread="7.2"/>
                    <measurement group_id="O4" value="-14.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI) Severity</title>
        <description>CGI is a clinician-reported scale for assessing severity of illness.
The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.</description>
        <time_frame>Baseline, 2 weeks, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>2.25 mg/Day</title>
            <description>SPM962 maintein dose: 2.25 mg/day</description>
          </group>
          <group group_id="O3">
            <title>4.5 mg/Day</title>
            <description>SPM962 maintein dose: 4.5mg/day</description>
          </group>
          <group group_id="O4">
            <title>6.75 mg/Day</title>
            <description>SPM962 maintein dose: 6.75 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI) Severity</title>
          <description>CGI is a clinician-reported scale for assessing severity of illness.
The sale scoring criteria are 1: Normal, not at all ill, 2: Borderline ill, 3: Mildly ill, 4: Moderately ill, 5: Markedly ill, 6: Severely ill, 7: Among the most extremely ill patients.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="83.6"/>
                    <measurement group_id="O3" value="92.9"/>
                    <measurement group_id="O4" value="86.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased to 1 or 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="41.1"/>
                    <measurement group_id="O4" value="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with CGI score 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects without improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3"/>
                    <measurement group_id="O2" value="16.4"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 at baseline and stayed at 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 at baseline and decreased to 1 or 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="46.4"/>
                    <measurement group_id="O4" value="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression (PGI) Improvement</title>
        <description>The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.</description>
        <time_frame>Baseline, 4 weeks and 6 weeks. The data at 6 weeks after dosing is shown.</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>2.25 mg/Day</title>
            <description>SPM962 maintein dose: 2.25 mg/day</description>
          </group>
          <group group_id="O3">
            <title>4.5 mg/Day</title>
            <description>SPM962 maintein dose: 4.5mg/day</description>
          </group>
          <group group_id="O4">
            <title>6.75 mg/Day</title>
            <description>SPM962 maintein dose: 6.75 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression (PGI) Improvement</title>
          <description>The PGI-I is a self-rated 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. Moderate and marked improvement = score of 1 or 2, Without improvement = score of 4, Marked and moderate aggravation = score of 6 or 7.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate and marked improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4"/>
                    <measurement group_id="O2" value="70.4"/>
                    <measurement group_id="O3" value="82.1"/>
                    <measurement group_id="O4" value="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate and marked aggravation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Pittsburgh Sleep Quality Index (PSQI)</title>
        <description>PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates “no difficulty” and 21 indicates “severe difficulty”. A decrease in the scores means improvement.
The data at 6 weeks after dosing is shown.</description>
        <time_frame>Baseline, every two weeks</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>2.25 mg/Day</title>
            <description>SPM962 maintein dose: 2.25 mg/day</description>
          </group>
          <group group_id="O3">
            <title>4.5 mg/Day</title>
            <description>SPM962 maintein dose: 4.5mg/day</description>
          </group>
          <group group_id="O4">
            <title>6.75 mg/Day</title>
            <description>SPM962 maintein dose: 6.75 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>The Pittsburgh Sleep Quality Index (PSQI)</title>
          <description>PSQI is a scale for assessing severity of sleep disorders. The score ranges from 0 to 21. 0 indicates “no difficulty” and 21 indicates “severe difficulty”. A decrease in the scores means improvement.
The data at 6 weeks after dosing is shown.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with ≥60% decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="23.2"/>
                    <measurement group_id="O4" value="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with ≥50% decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="39.3"/>
                    <measurement group_id="O4" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)</title>
        <description>Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.</description>
        <time_frame>Baseline, every two weeks</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>2.25 mg/Day</title>
            <description>SPM962 maintein dose: 2.25 mg/day</description>
          </group>
          <group group_id="O3">
            <title>4.5 mg/Day</title>
            <description>SPM962 maintein dose: 4.5mg/day</description>
          </group>
          <group group_id="O4">
            <title>6.75 mg/Day</title>
            <description>SPM962 maintein dose: 6.75 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcome Study (MOS) Short-Form 36-Item Health Survey (SF-36)</title>
          <description>Mean Change from baseline in MOS Short Form SF-36 to 6 weeks after dosing. SF-36 is a scale for assessing health status in clinical practice and research. The scores of 36 questions are summarized into 7 sub-scales. In each sub-scale which range is 0-100, a higher score indicates a better health status. Thus a increase in the scores means improvement.</description>
          <population>FAS, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="8.1"/>
                    <measurement group_id="O2" value="1.6" spread="9.6"/>
                    <measurement group_id="O3" value="2.8" spread="12.7"/>
                    <measurement group_id="O4" value="0.1" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="18.0"/>
                    <measurement group_id="O2" value="1.7" spread="18.7"/>
                    <measurement group_id="O3" value="1.3" spread="15.8"/>
                    <measurement group_id="O4" value="0.9" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="25.0"/>
                    <measurement group_id="O2" value="5.0" spread="28.0"/>
                    <measurement group_id="O3" value="1.7" spread="27.4"/>
                    <measurement group_id="O4" value="12.6" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="16.4"/>
                    <measurement group_id="O2" value="2.5" spread="10.5"/>
                    <measurement group_id="O3" value="4.6" spread="14.8"/>
                    <measurement group_id="O4" value="4.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="16.6"/>
                    <measurement group_id="O2" value="6.5" spread="17.2"/>
                    <measurement group_id="O3" value="3.6" spread="19.9"/>
                    <measurement group_id="O4" value="6.5" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="19.3"/>
                    <measurement group_id="O2" value="4.4" spread="17.0"/>
                    <measurement group_id="O3" value="1.1" spread="18.4"/>
                    <measurement group_id="O4" value="4.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="18.4"/>
                    <measurement group_id="O2" value="5.7" spread="18.4"/>
                    <measurement group_id="O3" value="4.2" spread="18.7"/>
                    <measurement group_id="O4" value="0.7" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IRLS Each Parameter</title>
        <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually ‘very severe’) to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.</description>
        <time_frame>Baseline, every two weeks</time_frame>
        <population>FAS, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo transdermal patch</description>
          </group>
          <group group_id="O2">
            <title>2.25 mg/Day</title>
            <description>SPM962 maintein dose: 2.25 mg/day</description>
          </group>
          <group group_id="O3">
            <title>4.5 mg/Day</title>
            <description>SPM962 maintein dose: 4.5mg/day</description>
          </group>
          <group group_id="O4">
            <title>6.75 mg/Day</title>
            <description>SPM962 maintein dose: 6.75 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>IRLS Each Parameter</title>
          <description>IRLS is a scale for assessing severity of restless legs syndrome symptoms. IRLS consists of ten questions. Each question is scored from 4 for the first (top) answer (usually ‘very severe’) to 0 for the last answer (usually none).
The sum of the score of each question serves as the scale score. The scale scoring criteria are: Mild (score 1-10); Moderate (score 11-20); Severe (score 21-30); Very severe (score 31-40). A decrease in the scores means improvement.
The percentage of subjects with -3 or -4 changes from baseline in each parameter at 6 weeks after dosing is shown.</description>
          <population>FAS, LOCF</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>-4 (RLS discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (RLS discomfort)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="16.1"/>
                    <measurement group_id="O4" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (need to move around due to RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (need to move around due to RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="16.1"/>
                    <measurement group_id="O4" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (discomfort relief by moving around)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (discomfort relief by moving around)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="9.1"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of RLS as a whole)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of RLS as a whole)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (RLS symptoms frequency)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (RLS symptoms frequency)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="26.8"/>
                    <measurement group_id="O4" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (average duration of RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (average duration of RLS symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="7.1"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of sleep disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of sleep disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (tiredness or sleepiness during the day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (tiredness or sleepiness during the day)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="5.4"/>
                    <measurement group_id="O4" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of impact on daily affaires)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.8"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of impact on daily affaires)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="3.6"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-4 (severity of mood disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-3 (severity of mood disturbance)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.5"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo transdermal patch</description>
        </group>
        <group group_id="E2">
          <title>2.25 mg/Day</title>
          <description>SPM962 maintein dose: 2.25 mg/day</description>
        </group>
        <group group_id="E3">
          <title>4.5 mg/Day</title>
          <description>SPM962 maintein dose: 4.5mg/day</description>
        </group>
        <group group_id="E4">
          <title>6.75 mg/Day</title>
          <description>SPM962 maintein dose: 6.75 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (11.1)J</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E3" events="29" subjects_affected="25" subjects_at_risk="58"/>
                <counts group_id="E4" events="35" subjects_affected="27" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="58"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Application Site Reaction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Application Site Erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="58"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="58"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="58"/>
                <counts group_id="E4" events="18" subjects_affected="14" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="58"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menses Irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Research and Development</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-3-6361-7366</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

